Foundry120 atlas

A single-cell atlas of the peripheral immune response to severe COVID-19

Download from source ↗

Dataset overview

Participants None
Samples None
Reuse readiness 4.1/10 evidence-backed score

A single-cell atlas of the peripheral immune response in patients with severe COVID-19.

Abstract

There is an urgent need to better understand the pathophysiology of Coronavirus disease 2019 (COVID-19), the global pandemic caused by SARS-CoV-2, which has infected more than three million people worldwide<sup>1</sup>. Approximately 20% of patients with COVID-19 develop severe disease and 5% of patients require intensive care<sup>2</sup>. Severe disease has been associated with changes in peripheral immune activity, including increased levels of pro-inflammatory cytokines<sup>3,4</sup> that may be produced by a subset of inflammatory monocytes<sup>5,6</sup>, lymphopenia<sup>7,8</sup> and T cell exhaustion<sup>9,10</sup>. To elucidate pathways in peripheral immune cells that might lead to immunopathology or protective immunity in severe COVID-19, we applied single-cell RNA sequencing (scRNA-seq) to profile peripheral blood mononuclear cells (PBMCs) from seven patients hospitalized for COVID-19, four of whom had acute respiratory distress syndrome, and six healthy controls. We identify reconfiguration of peripheral immune cell phenotype in COVID-19, including a heterogeneous interferon-stimulated gene signature, HLA class II downregulation and a developing neutrophil population that appears closely related to plasmablasts appearing in patients with acute respiratory failure requiring mechanical ventilation. Importantly, we found that peripheral monocytes and lymphocytes do not express substantial amounts of pro-inflammatory cytokines. Collectively, we provide a cell atlas of the peripheral immune response to severe COVID-19.

Study facts

Organism
Homo sapiens
Platform
Illumina NovaSeq 6000
Age group
—
Disease groups
—
Anatomical sites
peripheral blood

Data availability

  • Raw counts

File types RDS

Files and samples

Strengths & limitations for reuse

Strengths

  • Raw reads are advertised
  • Raw counts are advertised

Limitations

  • Not documented: processed matrices are advertised
  • Not documented: cell metadata are advertised
  • Not documented: participant counts are documented
Extraction evidence & provenance

Each extracted field is shown with the source excerpt and location used to resolve it.

Assay

FieldValueEvidence
assay.assay_type single-cell RNA sequencing
we applied single-cell RNA sequencing (scRNA-seq)

Section series, offset —

assay.library_chemistry Nextera XT DNA library preparation kit
Library preparation was performed with a Nextera XT DNA library preparation kit

Section samples, offset —

assay.platform Illumina NovaSeq 6000
Illumina NovaSeq 6000

Section samples, offset —

assay.reference_genome GRCh37
Genome_build: GRCh37 including the complete genome sequences of all SARS-CoV-2 strains sequenced from California before March 24, 2020

Section samples, offset —

assay.sequencing_type scrna_seq
we applied single-cell RNA sequencing (scRNA-seq)

Section series, offset —

Cohort

FieldValueEvidence
cohort.non_ibd_controls 6
6 healthy controls

Section series, offset —

Data_Assets

FieldValueEvidence
data_assets.raw_counts True
cell.counts.matrices.rds.gz

Section samples, offset —

data_assets.raw_reads True
GSE150728_RAW.tar

Section —, offset —

Specimens

FieldValueEvidence
specimens.anatomical_sites ['peripheral blood']
peripheral blood mononuclear cells (PBMCs)

Section series, offset —